Search publications

Publications

  • Codony S, Calvó-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Pérez C, Rodríguez-Franco MI, Pizarro J, Corpas R, Griñán-Ferré C, Pallàs M, Sanfeliu C, Vazquez M, Hammock BD, Feixas F and Vázquez S.

    From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis.

    JOURNAL OF MEDICINAL CHEMISTRY . 64(9): 5429-5446.

    [doi:10.1021/acs.jmedchem.0c01601]

  • Sala E, Vived C, Luna J, Saavedra-Ávila NA, Sengupta U, Castaño AR, Villar-Pazos S, Haba L, Verdaguer J, Ropero AB, Stratmann T, Pizarro J, Vazquez M, Nadal A, Lahti JM and Mora C.

    CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model.

    FRONTIERS IN IMMUNOLOGY . 12: 634797-634797.

    [doi:10.3389/fimmu.2021.634797]

  • Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza MI, Brea JM, Saez E, Oyarzabal J, Pineda-Lucena A, Pérez-Dueñas B, Pérez C, Rodríguez-Franco MI, Leiva R, Osuna S, Morisseau C, Hammock BD, Vazquez M and Vázquez S.

    2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis.

    JOURNAL OF MEDICINAL CHEMISTRY . 63(17): 9237-9257.

    [doi:10.1021/acs.jmedchem.0c00310]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.

    TRENDS PHARMACOL SCI . 41(3): 199-208.

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14.

    [doi:10.1038/s41392-020-0114-1]

  • Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vazquez M, Pizarro J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C and Muñoz-Berbel X.

    Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients.

    BIOSENSORS & BIOELECTRONICS . 136: 38-46. Number of citations: 4

    [doi:10.1016/j.bios.2019.04.015]

  • Zarei M, Pujol E, Quesada T, Villarroya F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Number of citations: 5

    [doi:10.1111/bph.14678]

  • Botteri G, Salvadó L, Gumà A, Hamilton DL, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Corrigendum to "The BACE1 product sAPP induces ER stress and inflammation and impairs insulin signaling" [Metab Clin Exp 85 (2018) 59-75].

    METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 101-102.

    [doi:10.1016/j.metabol.2019.04.009]

  • Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    The BACE1 product sAPPß induces ER stress and inflammation and impairs insulin signaling.

    METABOLISM-CLINICAL AND EXPERIMENTAL . 85: 59-75. Number of citations: 14

    [doi:10.1016/j.metabol.2018.03.005]

  • Palomer FX, Pizarro J and Vazquez M.

    Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

    TRENDS PHARMACOL SCI . 39(5): 452-467. Number of citations: 27

    [doi:10.1016/j.tips.2018.02.010]